Is this a revolution in Alzheimer's?

About this episode

The episode discusses the implications of FDA-approved anti-amyloid drugs for Alzheimer's treatment with expert Howard Fillit.

This week on The Pharma Letter Podcast, we’re joined by Howard Fillit, co-founder and chief science officer at the Alzheimer’s Drug Discovery Foundation (ADDF). As the FDA approval of anti-amyloid drugs like lecanemab and donanemab marks a new era in the treatment of Alzheimer’s, questions remain around cost, access, and real-world impact. A geriatrician and neuroscientist, Dr Fillit has argued for a broader approach to Alzheimer’s—one that targets not just amyloid, but the full biology...

People in this episode

Host: Simon Wentworth

Guest: Howard Fillit

Topics covered

• Alzheimer's treatment
• FDA approval
• anti-amyloid drugs
• healthcare access
• neuroscience

Keywords

• Alzheimer's
• FDA
• lecanemab
• donanemab
• healthcare
• neuroscience
• drug discovery

Mentioned in this episode

Organizations: Alzheimer’s Drug Discovery Foundation, FDA

Products: lecanemab, donanemab

More episodes of The Pharma Letter Podcast

• BenevolentAI CEO on the future of AI-led medicine · May 6, 2026 · 30 min
• ConcertAI CEO Eron Kelly on Big Tech's role in biotech · March 13, 2026 · 18 min
• How blood cancer treatment is evolving in the Middle East · December 8, 2025 · 22 min
• Nouscom bets on dual vaccine strategy to outsmart cancer · July 25, 2025 · 20 min
• Why Boehringer and GSK are betting on Ochre · May 23, 2025 · 19 min
• ICON's AI strategy: faster, smarter trials · May 8, 2025 · 16 min